Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

787 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.
Keystone EC, Curtis JR, Fleischmann RM, Furst DE, Khanna D, Smolen JS, Mease PJ, Schiff MH, Coteur G, Davies O, Combe B. Keystone EC, et al. Among authors: khanna d. J Rheumatol. 2011 Jun;38(6):990-6. doi: 10.3899/jrheum.100935. Epub 2011 Mar 1. J Rheumatol. 2011. PMID: 21362764 Free article. Clinical Trial.
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial.
Strand V, Smolen JS, van Vollenhoven RF, Mease P, Burmester GR, Hiepe F, Khanna D, Nikaï E, Coteur G, Schiff M. Strand V, et al. Among authors: khanna d. Ann Rheum Dis. 2011 Jun;70(6):996-1002. doi: 10.1136/ard.2010.143586. Epub 2011 Mar 17. Ann Rheum Dis. 2011. PMID: 21415050 Free PMC article. Clinical Trial.
Meloxicam in rheumatoid arthritis.
Ahmed M, Khanna D, Furst DE. Ahmed M, et al. Among authors: khanna d. Expert Opin Drug Metab Toxicol. 2005 Dec;1(4):739-51. doi: 10.1517/17425255.1.4.739. Expert Opin Drug Metab Toxicol. 2005. PMID: 16863437 Review.
Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in patients with early aggressive rheumatoid arthritis.
Amjadi SS, Maranian PM, Paulus HE, Kaplan RM, Ranganath VK, Furst DE, Khanna PP, Khanna D; Western Consortium of Practicing Rheumatologists. Amjadi SS, et al. Among authors: khanna pp, khanna d. J Rheumatol. 2009 Jun;36(6):1150-7. doi: 10.3899/jrheum.080959. Epub 2009 Apr 15. J Rheumatol. 2009. PMID: 19369459 Free PMC article.
Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis.
Weng HH, Ranganath VK, Khanna D, Oh M, Furst DE, Park GS, Elashoff DA, Sharp JT, Gold RH, Peter JB, Paulus HE; Western Consortium of Practicing Rheumatologists. Weng HH, et al. Among authors: khanna d. J Rheumatol. 2010 Mar;37(3):550-7. doi: 10.3899/jrheum.090818. Epub 2010 Jan 28. J Rheumatol. 2010. PMID: 20110517 Free PMC article.
Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort.
Ranganath VK, Yoon J, Khanna D, Park GS, Furst DE, Elashoff DA, Jawaheer D, Sharp JT, Gold RH, Keystone EC, Paulus HE; Western Consortium of Practicing Rheumatologists. Ranganath VK, et al. Among authors: khanna d. Ann Rheum Dis. 2007 Dec;66(12):1633-40. doi: 10.1136/ard.2006.065839. Epub 2007 May 1. Ann Rheum Dis. 2007. PMID: 17472996 Free PMC article.
787 results